Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | TXN | P10599 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417370 | 0.82 | PNP (0.66) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| 8-Aminoguanine SCHEMBL21761 | 0.80 | PNP (1.00) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL3428510 | 0.75 | PNP (0.59) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL9116 | 0.72 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL42760 | 0.72 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL6686388 | 0.72 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL843932 | 0.72 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL843215 | 0.72 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL22883 | 0.72 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL2051361 | 0.72 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| EP-2915815-B1 | NEW MODIFIED NUCLEIC ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016983-A1 | New Modified Nucleic Acid | RNGTT, RNASEH1, RNASE1 | PNP 278/4885MAPT 4356/4885KDM4E 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.